| Summary: | 碩士 === 國立臺北科技大學 === 有機高分子研究所 === 94 === Chronic viral hepatitis may lead to liver cirrhosis, and complications of liver cirrhosis may cause substantial morbidity and mortality. It is important to have early diagnosis for liver fibrosis and cirrhosis. Liver biopsy is the gold standard for the evaluation of hepatic fibrosis. The current diagnosis method has high risk. And, it is too expansive. Therefore, we have investigated into the expression of serum perlecan and α-dystroglycan in normal with liver disease free and patients with liver cirrhosis. Perlecan is a ubiquitous heparin sulfate proteoglycan that is an intrinsic constituent of all basement membranes and extracellular matrices. The heparan sulfate proteoglycans （HSPGs）play diverse roles in tumor biology by mediating adhesion and migration and cellular responses to mitogenic and angiogenic growth factors. Dystroglycan (DG), a non-integrin adhesion molecule, is a pivotal component of the dystrophin-glycoprotein complex that is expressed in skeletal muscle and in a wide variety of tissues, at the interface between the basement membrane (BM) and the cell membrane. Dystroglycan and perlecan are one of the extracellular matrix（ECM） components. Changes of ECM components may cause liver fibrosis. Recent studies also indicate that abnormalities in the expression of perlecan and DG frequently occur in human cancers and may play a role in both the process of tumor progression and in the maintenance of the malignant phenotype. We have used lectin blot to observe glycan expression of immunoprecipitated perlecan and dystroglycan from serum of liver cirrhosis patients and normal human with liver disease free as healthy control. But there is no difference between the serum samples from the patients with liver cirrhosis patients and healthy controls.
|
|---|
